Carnosine [corrected] increases efficiency of DOPA therapy of Parkinson's disease: a pilot study

Rejuvenation Res. 2008 Aug;11(4):821-7. doi: 10.1089/rej.2008.0716.


The addition of the neuropeptide carnosine (beta-alanyl-L-histidine) as a food additive to the basic protocol of Parkinson's disease treatment results in significant improvement of neurological symptoms, along with increase in red blood cell Cu/Zn-SOD and decrease in blood plasma protein carbonyls and lipid hydroperoxides, with no noticeable change in platelets MAO B activity. The combination of carnosine with basic therapy may be a useful way to increase efficiency of PD treatment.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Carnosine / administration & dosage*
  • Dihydroxyphenylalanine / administration & dosage*
  • Drug Synergism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monoamine Oxidase / metabolism
  • Oxidative Stress / drug effects
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Pilot Projects
  • Protein Carbonylation / drug effects
  • Superoxide Dismutase / metabolism
  • Treatment Outcome


  • Dihydroxyphenylalanine
  • Carnosine
  • Superoxide Dismutase
  • Monoamine Oxidase